Lab of Collaborative Research (Masutani Group)

Boron-captured neutron therapy and biological radiosensitization

Accelerator-based BNCT (boron neutron-capture therapy) system has been developed as a collaborative project of the NCC and industries. The biological responses in BNCT is being studied for optimization and finding biomarkers for BNCT. Biological radiosensitization strategy is being pursued though studying the responses of tumor and normal cells to particle and photon beam irradiation.

The studies of anti-cancer drugs targeting DNA

Poly(ADP-ribosylation) and other DNA damage response pathways and factors affecting the effectiveness of anti-cancer drugs including poly(ADP-ribose) polymerase (PARP) inhibitors and cisplatin are being studied. Identification and optimization of predictive and pharmacodynamic biomarkers for PARP inhibitors and other anti-cancer drugs are also being pursued.